OncoGenex Pharmaceuticals' OGX-011 granted FDA fast track status

[News]

OncoGenex Pharmaceuticals has announced that OGX-011, also known as custirsen sodium, received Fast Track designation from the U.S. Food & Drug Administration (FDA) in combination with docetaxel for progressive metastatic prostate cancer.

More... (http://www.news-medical.net/?id=40857)